Ceryvyn Therapeutics Limited
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||
| Net Income | $-162.8M | $-220.2M | $-142.5M | $-92.8M | $-45.3M | $-11.1M | $-15.0M |
| Depreciation & Amortization | — | — | — | — | — | — | — |
| Depreciation | — | — | $17.0K | $11.9K | $15.0K | $14.6K | $14.2K |
| Amortization | — | — | — | — | — | — | — |
| Stock-Based Compensation | $6.1M | $5.1M | $5.8M | $5.3M | $3.9M | $732.7K | $685.4K |
| Net Cash from Operating Activities | $-158.6M | $-161.0M | $-120.6M | $-71.3M | $-45.5M | $-5.7M | $-17.0M |
| Investing Activities | |||||||
| Capital Expenditures | $13.0K | $33.0K | $22.0K | $16.9K | $12.7K | $2.5K | $10.4K |
| Business Acquisitions | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-13.0K | $-33.0K | $-22.0K | $-16.9K | $656.5K | $333.2K | $239.8K |
| Financing Activities | |||||||
| Dividends Paid | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $34.8M | $243.7M | $167.3M | $171.6K | $116.9M | $33.2M | $9.1M |
| Net Change in Cash | — | — | — | — | — | — | — |
| Free Cash Flow | $-158.7M | $-161.0M | $-120.6M | $-71.4M | $-45.6M | $-5.7M | $-17.1M |